EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Hospital Universitario Son Espases
Palma, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Son Espases (12)
2023
2022
-
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial
European Journal of Cancer, Vol. 174, pp. 232-242
2021
2020
-
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464
-
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial
Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Nature Communications, Vol. 11, Núm. 1
-
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 33-43
2019
2018
-
Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90
2016
-
Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial
Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1601-1610
-
Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy
Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593
2006
-
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain
Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902